LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Cerrado

SectorSalud

0.46 4.55

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.44

Máximo

0.47

Métricas clave
By Trading Economics
Ingresos	-9.9M -48M
Ventas	1.8M 13M
Margen de beneficio	-362.728
Empleados	144
EBITDA	-10M -45M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	+738.64% upside

Dividendos
By Dow Jones
Próximas Ganancias	18 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-418M 129M
Apertura anterior	-4.09
Cierre anterior	0.46

Noticias sobre sentimiento de mercado

By Acuity

50%

133 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.06 / 1.23 Soporte y Resistencia

Gossamer Bio Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 mar 2026, 21:14 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15 mar 2026, 21:14 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16 mar 2026, 00:00 UTC

Noticias de Eventos Importantes

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15 mar 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15 mar 2026, 23:44 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15 mar 2026, 23:35 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15 mar 2026, 23:00 UTC

Adquisiciones, fusiones, absorciones

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15 mar 2026, 22:37 UTC

Charlas de Mercado

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15 mar 2026, 22:18 UTC

Charlas de Mercado

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15 mar 2026, 22:14 UTC

Ganancias

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15 mar 2026, 22:00 UTC

Noticias de Eventos Importantes

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 mar 2026, 22:00 UTC

Noticias de Eventos Importantes

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 mar 2026, 03:00 UTC

Noticias de Eventos Importantes

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14 mar 2026, 15:00 UTC

Noticias de Eventos Importantes

Iran War Delivers Windfall to America's Oil Country -- WSJ

14 mar 2026, 02:03 UTC

Ganancias

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14 mar 2026, 01:32 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14 mar 2026, 00:29 UTC

Adquisiciones, fusiones, absorciones

13D Filings -- Barrons.com

13 mar 2026, 22:27 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 mar 2026, 22:13 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 mar 2026, 22:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 mar 2026, 22:00 UTC

Adquisiciones, fusiones, absorciones

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

13 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 20:02 UTC

Charlas de Mercado

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 mar 2026, 19:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 mar 2026, 19:35 UTC

Noticias de Eventos Importantes

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc Esperado

Precio Objetivo

By TipRanks

738.64% repunte

Estimación a 12 meses

Media 3.69 USD 738.64%

Máximo 15 USD

Mínimo 0.3 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.06 / 1.23Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

133 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.